Autopsy report · NCT01763437

Intralesional Tetracycline Injection in the Treatment of Chalazia

“Investigator left the institution”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Early Phase 1

Sponsor

The Cleveland Clinic

Sponsor type

University, hospital or other

Conditions

Chalazia; Chalazion

Interventions

Tetracycline

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
  “Investigator Left Institution” (96% match in meaning)
• Use of Cast Iron Pots to Improve Maternal Anemia
  “Original investigator has left the institution.” (94% match in meaning)
• Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
  “Principle investigator left the institution” (93% match in meaning)
• Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations
  “Investigator departed from institution” (93% match in meaning)
• Pupillometry Guided Remifentanil Administration In Pediatric Anesthesia
  “Principal investigator left the institution” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.